2-(4-methyl-5-(4-methylpyridin-2-yl)thiazol-2-ylamino)-2-thiazoline | 289468-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-methyl-5-(4-methylpyridin-2-yl)thiazol-2-ylamino)-2-thiazoline
• 英文别名: N-(4,5-dihydro-1,3-thiazol-2-yl)-4-methyl-5-(4-methylpyridin-2-yl)-1,3-thiazol-2-amine
• CAS: 289468-55-9
• 化学式: C₁₃H₁₄N₄S₂
• 分子量: 290.413
• InChiKey: AKFGUXSDHQYFDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(甲基巯基)-2-噻唑啉 、 2-amino-4-methyl-5-(4-methylpyridin-2-yl)-thiazole 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙二醇甲醚 为溶剂， 生成 2-(4-methyl-5-(4-methylpyridin-2-yl)thiazol-2-ylamino)-2-thiazoline
  参考文献：
  名称：

  Pyridine compounds and their pharmaceutical use

  摘要：

  根据所附的规格说明书，本发明的化合物(I)和药用可接受的盐具有强烈的抑制一氧化氮(NO)生成的活性，并且可用于预防或治疗由NOS（一氧化氮合酶）介导的疾病，例如成人的呼吸窘迫综合征、心肌炎、滑膜炎、败血症休克、胰岛素依赖型糖尿病、溃疡性结肠炎、脑梗塞、类风湿性关节炎、骨关节炎、骨质疏松症、系统性红斑狼疮、器官移植排斥反应、哮喘、疼痛、溃疡等人类和动物的疾病。

  公开号：

  US06521643B1

文献信息

• PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1157022A1

  公开（公告）日：2001-11-28
• US6521643B1
  申请人：——

  公开号：US6521643B1

  公开（公告）日：2003-02-18
• [EN] PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE<br/>[FR] COMPOSES PYRIDINE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2000049015A1

  公开（公告）日：2000-08-24

  A compound of formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NOS(nitric oxide synthase)-mediated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, insulin-dependent diabetes mellitus, ulcerative colitis, cerebral infarction, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, pain, ulcer, and the like in human being and animals.
• Pyridine compounds and their pharmaceutical use
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06521643B1

  公开（公告）日：2003-02-18

  A compound of formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NOS(nitric oxide synthasey)-mediated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, insulin-ependent diabetes mellitus, ulcerative colitis, cerebral infarction, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, pain, ulcer, and the like in human being and animals.

  根据所附的规格说明书，本发明的化合物(I)和药用可接受的盐具有强烈的抑制一氧化氮(NO)生成的活性，并且可用于预防或治疗由NOS（一氧化氮合酶）介导的疾病，例如成人的呼吸窘迫综合征、心肌炎、滑膜炎、败血症休克、胰岛素依赖型糖尿病、溃疡性结肠炎、脑梗塞、类风湿性关节炎、骨关节炎、骨质疏松症、系统性红斑狼疮、器官移植排斥反应、哮喘、疼痛、溃疡等人类和动物的疾病。